By ICN GroupChemical, June 02, 2020

AGC acquires AstraZeneca's biopharma plant

AGC will prepare for the plant to resume full-scale operations by April 2021.

AGC Inc. has announced the purchase of a biopharmaceutical commercial manufacturing facility in Boulder, Colorado, USA. The facility, formerly owned by AstreaZeneca, will provide AGC with additional capacity and significantly larger production scale. AGC will prepare for the plant to resume full-scale operations by April 2021.
AGC Biologics, a U.S.-based CDMO subsidiary of the company, utilizes mammalian cells and microorganisms to provide a variety of high value-added services that range from process development to scale-up, and manufacturing of biopharmaceutical APIs. It’s contract base covers needs from early stage clinical trials through commercial manufacturing, with particular strength in its flexible single-use production lines fit for producing multiple products and products with volume volatility.
The Colorado facility is a large-scale biopharmaceutical manufacturing plant that houses two 20,000-liter (total volume) stainless steel mammalian cell bioreactors, and is well suited for higher volume commercial production. It also has more than twenty acres of land providing opportunities for future expansions. The existing plant has space for up to four more 20,000-liter bioreactors. With its expanded customer portfolio, as well as current projects advancing into commercial phase, AGC Biologics was looking to expand its footprint. This addition will enable AGC Biologics to support a wider range of commercial demand, and fulfill the needs of the pharmaceutical industry better.

Related News

View All Chemical

Perdaman Industries selects Saipem for building a $4.5 bn urea plant in Australia

The scope of work of the joint venture includes engineering, construction, pre-commissioning and commissioning of the urea plant including all utilities, urea handling, storage tanks and site civil buildings.

PolyOne completes masterbatches acquisition from Clariant, changes name to Avient

With this acquisition, Avient now expects over 85% of adjusted EBITDA to be generated from specialty applications.

Availability of 2 lakh MT of imported fertilizers by RCF

The fertilizers include DAP, APS (20:20:0:13) and NPK (10:26:26) to the farmers for the current Kharif sowing season in the country.